TYK Medicines, Inc Announces Completion of H Share Full Circulation

Key Points from the Announcement

• H Share Full Circulation Completed: TYK Medicines, Inc has successfully completed the conversion of 4,608,000 Unlisted Shares into H shares. The process was finalized on March 4, 2026, with the converted H shares set to be listed and commence trading on the Hong Kong Stock Exchange at 9:00 a.m. on March 5, 2026.
• Shareholding Structure Change: Before the conversion, the company had 375,457,818 H shares and 4,608,000 Unlisted shares. After the conversion, there are now 380,065,818 H shares, representing 100% of the share capital. All unlisted shares have been converted, resulting in a simplified capital structure composed solely of H shares.
• Regulatory Approvals: The conversion followed the issuance of a Filing Notice by the China Securities Regulatory Commission (CSRC) and the listing approval from the Hong Kong Stock Exchange, indicating full regulatory compliance.
• Board Statement: Dr. WU Yusheng, Chairman, Executive Director, and CEO, confirmed the completion and encouraged shareholders and potential investors to exercise caution when dealing in the Company’s H shares.

Potential Price-Sensitive Information

• Market Implications: The transition to full H share circulation eliminates the distinction between public H shares and unlisted shares, potentially improving liquidity and transparency in trading. Investors may view this as a positive development, since all shares are now freely tradable on the Hong Kong Exchange, which can enhance market confidence and potentially support share price performance.
• Risk Factors: The announcement includes a caution to shareholders and potential investors. This suggests there may be volatility as the newly converted shares enter the market, impacting supply and perhaps near-term price behavior.

Detailed Information for Investors

• Share Capital Breakdown:
  • Before conversion: 375,457,818 H shares (98.79%), 4,608,000 Unlisted shares (1.21%)
  • After conversion: 380,065,818 H shares (100.00%), 0 Unlisted shares (0%)
• Timing: Listing of the converted H shares begins at 9:00 a.m. on March 5, 2026.
• Board Composition: The Board consists of a mix of executive, non-executive, and independent non-executive directors, highlighting strong governance:
  • Executive Director: Dr. WU Yusheng
  • Non-executive Directors: Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao, Dr. ZHU Xiangyang
  • Independent Non-executive Directors: Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua, Mr. JIANG Xiaolin

Investor Takeaways

• The completion of H share full circulation is a structural change that may positively affect liquidity and valuation for TYK Medicines, Inc.
• Investors should monitor the share price closely in the near term, as the converted shares could introduce additional trading activity and volatility.
• The company’s strong regulatory compliance and transparent governance are positive signals for long-term investors.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consult their financial advisors and carefully consider all risk factors before making investment decisions. The completion of H share full circulation may have implications for share trading and price performance, but past performance is not indicative of future results.

View TYK MEDICINES-B Historical chart here